Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
4(100.0%)
4Total
N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04577456Not ApplicableCompleted

Chyme Reinfusion for Type 2 Intestinal Failure

Role: collaborator

NCT06364215Not ApplicableTerminated

Posterior Wall Substrate Modification Using Irreversible Electroporation for Paroxysmal Atrial Fibrillation

Role: collaborator

NCT02115503Terminated

A Prospective, Global, Multi-center, Treatment Registry Study of Intravenous Immunoglobulin Maintenance Therapy in Alloantibody Positive Renal Allograft Recipients

Role: lead

NCT05385224Not ApplicableCompleted

PillSense System for Detecting UGI Bleed

Role: collaborator

NCT05959395Not ApplicableUnknown

Hyperthermia Treatment Added to Chemotherapy Standard of Care for Pancreatic Tumors

Role: collaborator

All 5 trials loaded